Matching articles for "mesalamine"
Issue 1724 · March 17, 2025
Guselkumab (Tremfya) for Ulcerative Colitis

The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):46-8 doi:10.58347/tml.2025.1724d
The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of UC; risankizumab (Skyrizi) and mirikizumab (Omvoh) were approved earlier.
Issue 1715 · November 11, 2024
Risankizumab (Skyrizi) for Ulcerative Colitis

The injectable interleukin (IL)-23 antagonist risankizumab-rzza ( Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):182-4 doi:10.58347/tml.2024.1715d
The injectable interleukin (IL)-23 antagonist risankizumab-rzza ( Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.
Issue 1698 · March 18, 2024
Mirikizumab (Omvoh) for Ulcerative Colitis

The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective…

Med Lett Drugs Ther. 2024 Mar 18; 66(1698):46-7 doi:10.58347/tml.2024.1698c
The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective IL-23 antagonist to be approved for this indication. Ustekinumab (Stelara) , an IL-12/23 antagonist, was approved for treatment of UC in 2019. The IL-23 antagonist risankizumab (Skyrizi) is approved for treatment of Crohn's disease.
Issue 1690 · November 27, 2023
Etrasimod (Velsipity) for Ulcerative Colitis

The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod ( Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):187-9 doi:10.58347/tml.2023.1690b
The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod ( Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the second oral S1P receptor modulator to be approved in the US for this indication; ozanimod (Zeposia) was the first.
Issue 1680 · July 10, 2023
Drugs for Inflammatory Bowel Disease

Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have…

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):105-12 doi:10.58347/tml.2023.1680a
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Issue 1680 · July 10, 2023
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View the Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e115-9 doi:10.58347/tml.2023.1680d
View the Table: Some Drugs for Inflammatory Bowel Disease
Issue 1680 · July 10, 2023
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View the Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e115-9 doi:10.58347/tml.2023.1680d
View the Table: Some Drugs for Inflammatory Bowel Disease
Issue 1658 · September 5, 2022
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):142-4
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Issue 1633 · September 20, 2021
Ozanimod (Zeposia) for Ulcerative Colitis

The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod ( Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative…

Med Lett Drugs Ther. 2021 Sep 20; 63(1633):147-51
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod ( Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Issue 1550 · July 2, 2018
Drugs for Inflammatory Bowel Disease

Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection.…

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):107-14
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
Issue 1550 · July 2, 2018
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View Expanded Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e117-22
View Expanded Table: Some Drugs for Inflammatory Bowel Disease
Issue 1550 · July 2, 2018
Table: Drugs for Ulcerative Colitis (online only)

View Table: Drugs for Ulcerative Colitis

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e114
View Table: Drugs for Ulcerative Colitis
Issue 1511 · January 2, 2017
Ustekinumab (Stelara) for Crohn's Disease

The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of…

Med Lett Drugs Ther. 2017 Jan 2; 59(1511):5-6
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.
Issue 1481 · November 9, 2015
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis

The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC)…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):154
The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Budesonide is also available as oral extended-release tablets (also branded as Uceris ) for use in patients with UC and as oral enteric-coated tablets ( Entocort EC , and generics) for treatment of Crohn's disease.
Issue 1451 · September 15, 2014
Vedolizumab (Entyvio) for Inflammatory Bowel Disease

The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to,…

Med Lett Drugs Ther. 2014 Sep 15; 56(1451):86-8
The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri) , another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.
Issue 1448 · August 4, 2014
Drugs for Inflammatory Bowel Disease

Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is…

Med Lett Drugs Ther. 2014 Aug 4; 56(1448):65-72
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol , Asacol HD , Lialda , and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine ( Azulfidine , and generics), balsalazide ( Colazal , and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa , and generics) and as a rectal suppository (Canasa) .
Issue 1439 · March 31, 2014
Golimumab (Simponi) for Ulcerative Colitis

The FDA has approved golimumab ( Simponi – Janssen), a fully human monoclonal antibody specific for tumor necrosis factor (TNF) alpha, for induction and maintenance of remission in patients with moderate to…

Med Lett Drugs Ther. 2014 Mar 31; 56(1439):25-6
The FDA has approved golimumab ( Simponi – Janssen), a fully human monoclonal antibody specific for tumor necrosis factor (TNF) alpha, for induction and maintenance of remission in patients with moderate to severe ulcerative colitis who do not respond to or cannot tolerate other therapies or who require continuous treatment with corticosteroids. Golimumab was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is the third TNF inhibitor to be approved for use in ulcerative colitis.
Issue 1412 · March 18, 2013
Budesonide (Uceris) for Ulcerative Colitis

The FDA has approved a new extended-release formulation of the corticosteroid budesonide ( Uceris – Santarus) for induction of remission in patients with mild to moderate ulcerative colitis.

Med Lett Drugs Ther. 2013 Mar 18; 55(1412):23
The FDA has approved a new extended-release formulation of the corticosteroid budesonide ( Uceris – Santarus) for induction of remission in patients with mild to moderate ulcerative colitis.
Issue 115 · March 1, 2012
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of…

Treat Guidel Med Lett. 2012 Mar; 10(115):19-28
Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of Gastroenterology.
Issue 85 · September 1, 2009
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is…

Treat Guidel Med Lett. 2009 Sep; 7(85):65-74
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.
Issue 1312 · May 18, 2009
Encapsulated Mesalamine Granules (Apriso) for Ulcerative Colitis

Apriso (Salix) is a new formulation of mesalamine (5-aminosalicylic acid; 5-ASA) approved by the FDA for maintenance of remission in mild to moderate ulcerative colitis (UC). Mesalamine is a locally acting…

Med Lett Drugs Ther. 2009 May 18; 51(1312):38-9
Apriso (Salix) is a new formulation of mesalamine (5-aminosalicylic acid; 5-ASA) approved by the FDA for maintenance of remission in mild to moderate ulcerative colitis (UC). Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease. Various mesalamine formulations have been developed to target drug delivery to areas of the small intestine and colon. Most of these agents require frequent dosing and have a high pill burden. The newest products - Lialda, introduced in 2007,1 and now Apriso - can be dosed once daily.
Issue 1287 · June 2, 2008 Free
Correction: Natalizumab (Tysabri) for Crohn's Disease

The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement:…

Med Lett Drugs Ther. 2008 Jun 2; 50(1287):44
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "post-marketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is recognized as an important predictor of severe liver injury that may lead to [emphasis added] death or the need for a liver transplant in some patients." Also, in the last sentence of the Conclusion, we should have said: "Because of the risk of serious hepatic toxicity and the rare but even more serious risk of developing progressive multifocal leukoencephalopathy, it should be used only in patients who have not responded to other drugs, including a TNF inhibitor." The italicized words should be substituted for "it is FDA-approved for use." Download: U.S. English
Issue 1285 · May 5, 2008
Natalizumab (Tysabri) for Crohn's Disease

Natalizumab ( Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors…

Med Lett Drugs Ther. 2008 May 5; 50(1285):34-6
Natalizumab ( Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML). It is now available for treatment of both MS and CD through a restricted distribution program.
Issue 1257 · March 26, 2007
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis

A once-daily oral formulation of mesalamine ( Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.

Med Lett Drugs Ther. 2007 Mar 26; 49(1257):25-6
A once-daily oral formulation of mesalamine ( Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
Issue 1122 · January 21, 2002
Budesonide (Entocort EC) For Crohn's Disease

Budesonide ( Entocort EC — AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19) , has been approved for oral…

Med Lett Drugs Ther. 2002 Jan 21; 44(1122):6-8
Budesonide ( Entocort EC — AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19) , has been approved for oral treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon. Both oral budesonide and budesonide enemas have been available for years in Europe and Canada for treatment of inflammatory bowel disease.
Issue 1109 · July 23, 2001
Oral Balsalazide (Colazal) For Ulcerative Colitis

Balsalazide disodium (Colazal) , a prodrug of mesalamine, was marketed in the US this year for oral treatment of mildly to moderately active ulcerative colitis. Oral formulations of mesalamine have been…

Med Lett Drugs Ther. 2001 Jul 23; 43(1109):62-3
Balsalazide disodium (Colazal) , a prodrug of mesalamine, was marketed in the US this year for oral treatment of mildly to moderately active ulcerative colitis. Oral formulations of mesalamine have been available in the US for nine years for treatment and maintenance of remissions and olsalazine, which is a dimer of mesalamine, is marketed for maintenance of remissions but not for treatment. Balsalazide has been available in Europe for four years.
Issue 831 · November 16, 1990
Olsalazine

Olsalazine sodium ( Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain…

Med Lett Drugs Ther. 1990 Nov 16; 32(831):105-6
Olsalazine sodium ( Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine ( Azulfidine ; and others).
Issue 766 · May 20, 1988
Mesalamine For Ulcerative Colitis

Mesalamine ( Rowasa - Reid-Rowell), probably better known as 5-aminosalicylic acid (5-ASA) and also called mesalazine in some other countries, was recently marketed in the USA as an enema for treatment of mild…

Med Lett Drugs Ther. 1988 May 20; 30(766):53-4
Mesalamine ( Rowasa - Reid-Rowell), probably better known as 5-aminosalicylic acid (5-ASA) and also called mesalazine in some other countries, was recently marketed in the USA as an enema for treatment of mild to moderate distal ulcerative colitis, including ulcerative proctosigmoiditis and ulcerative proctitis.